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Ribosome Display: A Technology for Selecting  
and Evolving Proteins from Large Libraries
Birgit Dreier and Andreas Plückthun 
Abstract
The selection and concomitant affinity maturation of proteins to bind to user-defined target molecules 
have become a key technology in biochemical research, diagnostics, and therapy. One of the most potent 
selection technologies for such applications is ribosome display. It works entirely in vitro, and this has two 
important consequences. First, since no transformation of any cells is required, libraries with much 
greater diversity can be handled than with most other techniques. Second, since a library does not have 
to be cloned and transformed, it is very convenient to introduce random errors in the library by PCR-
based methods and select improved binders. Thus, a true directed evolution, an iteration between ran-
domization and selection over several generations, can be conveniently carried out, e.g., for affinity 
maturation. Ribosome display has been used successfully for the selection of antibody fragments and 
other binding proteins, such as Designed Ankyrin Repeat Proteins (DARPins).
Key words: Ribosome display, In vitro selection, In vitro translation, Designed ankyrin repeat pro-
teins, Affinity maturation
In order to select and evolve proteins or peptides from a library to 
bind to any chosen target of interest, different selection strategies 
can be applied. All technologies have in common that the pheno-
type (peptide or protein scaffold) is physically linked to the genetic 
information (DNA or mRNA). We term “in vivo” those technolo-
gies that require transformation of cells with a library, as needed, 
for example, in phage display (1). In contrast, “in vitro” technolo-
gies do not require any transformation of cells with the library. 
Examples are ribosome display (2, 3) or mRNA display (4, 5). In 
each case, selection of highly specific binders is performed over 
multiple rounds of selection, starting from a library of peptides or 
proteins with a natural or designed scaffold (Fig. 1).
1.  Introduction
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Ribosome display has some major advantages compared to in 
vivo selection strategies. First, the library size is not restricted to 
limitations in transformation efficiency, which for Escherichia coli 
usually is 109–1010 per microgram of DNA and significantly lower 
when a ligation mixture is used. In ribosome display, library size 
is only limited by the number of ribosomes present in the in vitro 
translation and can be as high as 1012–1014. Second, while in the 
living cell protein biosynthesis and folding occur in a given envi-
ronment, the environment using an in vitro selection system can 
be manipulated and optimized for expression, folding, and stabil-
ity of the library members. This can be exploited for stability 
selection (6, 7). Third, the diversity of the library members can be 
easily manipulated at any selection step by introduction of addi-
tional mutations using DNA shuffling (8) and/or error-prone 
PCR (9). This is perhaps the factor of greatest practical utility. 
In other technologies, after each randomization step, a new 
library needs to be ligated and transformed. In ribosome display, 
an additional randomization step merely alters the method of 
library amplification. Therefore, ribosome display is particularly 
suited for directed evolution projects over many generations.
Ribosome display selections have been first exploited for pep-
tides (10), but the true advantage of directed evolution by using 
error-prone PCR methods was only borne out with proteins, and 
antibody scFv fragments (3, 7, 11, 12) were the first protein used. By 
using very stringent selections for affinity, antibody scFv fragments 
have been evolved to affinities as high as 5 pM or even 1 pM (12, 13). 
By choosing an appropriate selection pressure, properties other than 
affinity could be optimized, such as, for example, stability (7).
Over the last years also new protein scaffolds, with more desir-
able biophysical properties than antibody fragments, have been 
investigated. Among the most promising scaffolds are the D esigned 
Ankyrin Repeat P roteins (DARPins), which are devoid of disul-
fide bonds, highly soluble, and highly stable, and therefore achieve 
high expression levels in E. coli (14). They also fold well in the 
in vitro translation inherent in ribosome display. Using ribosome 
display DARPins have been evolved to bind various targets with 
affinities all the way down to the picomolar range (15–20). In 
general, probably because of their robust in vitro folding, DARPins 
are enriched over fewer rounds than antibody fragments.
Taken together, ribosome display is an ideal tool to select and 
evolve proteins with predefined binding properties from large 
libraries.
 1. 96-well Maxisorp plates (Nunc, No. 442404) or strips.
 2. Adhesive plate sealers (Thermo Scientific, No. AB-0580).
2.  Materials
2.1.  General
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 3. Sterile, RNase-free ART filter tips (Molecular Bio Products).
 4. Sterile, RNase-free HydroLogix 1.5 and 2.0-ml tubes 
(Molecular Bio Products, No. 3448 or No. 3434).
 5. Roche high pure RNA isolation kit (Roche, No. 11828665001).
 6. illustra MicroSpin™ G-50 Columns (GE Healthcare, No. 
27-5330-01).
 7. NucleoSpin® Extract II DNA purification kit (Macherey-
Nagel, No. 740609.50).
 1. Tris-buffered saline (TBS): 50 mM Tris, 150 mM NaCl; 
adjust pH to 7.4 with HCl at 4°C; filter through 0.22 mm.
 2. TBST: TBS containing 0.05% Tween-20.
 3. Stock solutions for wash buffer (WB) and elution buffer (EB): 
2 M Tris-acetate; adjust pH to 7.5 at 4°C with acetic acid, 
5 M NaCl, 2 M magnesium acetate, 250 mM EDTA; adjust 
pH to 8.0 by NaOH addition. Sterile filter all solutions. For 
alternative buffer composition see Note 2.
 4. WB/Tween-20 (WBT): 50 mM Tris-acetate pH 7.5, 150 mM 
NaCl, 50 mM magnesium acetate, 0.05% Tween-20; adjust 
pH to 7.5 with acetic acid at 4°C; filter through 0.22 mm.
 5. EB: 50 mM Tris-acetate pH 7.5, 150 mM NaCl, 25 mM 
EDTA; adjust pH to 7.5 with HCl at 4°C; filter through 
0.22 mm.
 6. Saccharomyces cerevisiae RNA (BioChemica, No. 83847): dis-
solve to 25 mg/ml in H2O, aliquot and store at −20°C.
 7. 10% BSA in H2O: filter through 0.22 mm and store at 
−20°C.
 8. Neutravidin and/or streptavidin (Pierce, No. 31000 or No. 
21125): 1.2 mg/ml (20 mM) in TBS and store at −20°C.
 9. Streptavidin-coated magnetic beads (MyOne T1; Invitrogen, 
No. 65602).
 10. Reagents for biotinylation of the target: either for chemical 
biotinylation a NHS-biotin reagent [e.g., from Pierce 
EZ-linkTM SulfoNHS-LC-biotin (No. 21335)] or for enzy-
matic biotinylation of an AviTag using the E. coli biotinyla-
tion enzyme BirA (21) (reagents from Avidity).
 1. 6 M LiCl; filter through 0.22 mm pores.
 2. 3 M sodium acetate; filter through 0.22 mm pores.
 3. 70% EtOH diluted with H2O and 100% EtOH; filter through 
0.22 mm pores.
 4. illustra MicroSpin™ G-50 Columns (GE Healthcare, No. 
27-5330-01).
 5. DNAseI (10 U/ml; Roche, No. 04716728001).
2.2. Reagents for 
Selection (See Note 1)
2.3. Reagents  
for mRNA Cleanup 
After In Vitro 
Transcription
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 1. Primer dissolved to 100 mM in H2O; aliquot and store at −20°C.
EWT5s: 5¢-TTCCTCCATGGGTATGAGAGGATCG-3¢
WTC4: 5¢-TTTGGGAAGCTTTTGCAGGATTTCAGC-3¢
T7B: 5¢-ATACGAAATTAATACGACTCACTATAGGGAGA
CC ACAACGG-3¢
tolAk: 5¢-CCGCACACCAGTAAGGTGTGCGGTT TCAG-
TTG CCGCTTTCTTTCT-3¢
 2. AffinityScript™ Multiple Temperature Reverse Transcriptase 
(50 U/ml; Stratagene, No. 600107) and 10× buffer; see Note 3.
 3. 100 mM DTT in H2O; aliquot and store at −20°C.
 4. RNasin® Ribonuclease Inhibitor (20–40 U/ml; Promega, No. 
N2115).
 5. VentR
® DNA Polymerase (2 U/ml; New England Biolabs, 
No. M0254S) and 10× Thermopol buffer; see Note 4.
 6. Platinum® Taq DNA Polymerase (5 U/ml; Invitrogen, No. 
10966083) and 10× polymerase buffer.
 7. dNTPs: 5 mM each (Eurogentec, No. NU-0010-10); aliquot 
and store at −20°C.
 8. Nucleotide analogs dPTP and 8-oxo-dGTP (Jena Biosciences)
at a concentration of 100 mm.
 9. Dimethyl sulfoxide (DMSO; Fluka, 41640).
 10. Restriction endonucleases: BamHI (20 U/ml; No. R0136L), 
HindIII (20 U/ml; No. R0104L), NcoI (10 U/ml; No. 
R0193L), and 10× buffer all from New England Biolabs.
 11. T4 DNA ligase (5 U/ml; Fermentas, No. EL0014) and 10× 
ligase buffer.
 12. Ribosome display vector pRDV (GenBank accession code 
AY327136; please note the revised sequence) (16).
 1. T7 RNA polymerase (20 U/ml; Fermentas, No. EP0111); 
see Note 5.
 2. RNasin® Ribonuclease Inhibitor (20–40 U/ml; Promega, No. 
N2115).
 3. 100 mM DTT in H2O; aliquot and store at −20°C.
 4. T7 RNA polymerase buffer (5×): 1 M HEPES, 150 mM 
magnesium acetate, 10 mM spermidine, 200 mM DTT; 
adjust pH to 7.6 with KOH; aliquot and store at −20°C.
 5. 50 mM NTP mix: 50 mM adenosine 5¢-triphosphate (ATP; 
Sigma-Aldrich, No. A2383), 50 mM uridine 5¢-triphosphate 
(UTP; Sigma-Aldrich, No. U6625), 50 mM guanosine 
5¢-triphosphate (GTP; Sigma-Aldrich, No. G8877), 50 mM 
cytidine 5¢-triphosphate (CTP; Sigma-Aldrich, No. C1506) 
in H2O; aliquot and store at −20°C.
2.4. Reagents  
for Reverse 
Transcription, PCR  
and Cloning
2.5. Reagents for In 
Vitro Transcription
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 1. Protein disulfide isomerase (PDI; Sigma-Aldrich, No. P3818): 
22 mM in H2O; aliquot and store at −80°C.
 2. Heparin (Sigma-Aldrich, No. H4784) stock solution: 
200 mg/ml heparin in H2O (do not filter); aliquot and store 
at −20°C.
 3. Methionine (Sigma-Aldrich, No. M9625): 200 mM l-methi-
onine in H2O (do not filter); aliquot and store at −20°C.
 4. STOP mix: 1 ml WBT buffer/0.5% BSA plus 12.5 ml heparin 
stock solution (see above).
 1. E. coli strain MRE600 (ATCC 29417) (22) lacking ribonu-
clease I activity.
 2. Incomplete rich medium: 5.6 g KH2PO4, 28.9 g K2HPO4, 
10 g yeast extract, 15 mg thiamine for 1 l medium. Autoclave 
and add 50 ml 40 % glucose (w/v) and 10 ml 0.1 M magne-
sium acetate, both sterile filtered.
 3. S30 buffer: 10 mM Tris-acetate (pH 7.5 at 4°C), 14 mM 
magnesium acetate, 60 mM potassium acetate. Chill to 4°C 
before use.
 4. Preincubation mix (must be prepared directly before use): 
3.75 ml 2 mM Tris-acetate (pH 7.5 at 4°C), 71 ml 3 M mag-
nesium acetate, 75 ml amino acid mix (10 mM of each of the 
20 amino acids; Fluka, No. LAA21), 300 ml 0.2 M ATP, 50 U 
pyruvate kinase (Fluka, No. 83328), 0.2 g phosphoenolpyru-
vate trisodium salt (Fluka, No. 79435); add to 10 ml H2O.
 1. Set up premixA (the final concentration will be fivefold lower 
in the final volume of the in vitro translation reaction; see 
Subheading 3.4): 250 mM Tris-acetate (from a 2 M stock 
solution, pH 7.5 at 4°C), 18 mM anti-ssrA oligonucleotide 
(5¢-TTAAGCTGCTAAAGCGTAGTTTTCGTCGTTTGC-
GACTA-3¢) from a 200 mM stock solution, 1.75 mM of each 
amino acid except for methionine, 10 mM ATP from an 1 M 
stock solution, 2.5 mM GTP from a 0.2 M stock solution, 
5 mM cAMP (Sigma-Aldrich, No. A6885) from 0.4 M stock 
solution, 150 mM acetyl phosphate (Sigma-Aldrich, No. 
A0262) from 2 M stock solution, 2.5 mg/ml E. coli tRNA 
from strain MRE600 (Roche, No. 10109541001) from a 
25 mg/ml stock solution, 0.1 mg/ml folinic acid (Sigma-
Aldrich, No. 47612) from 10 mg/ml stock solution.
 2. Set up an in vitro translation reaction (see Subheading 3.4), 
and use the above premixA but titrate the optimal concentra-
tion of the following components for the final premixZ com-
position to achieve optimal performance of each newly 
generated S30 extract. Optimize the final concentrations in 
the order shown:
2.6. Reagents for  
In Vitro Translation
2.6.1. S30 Extract
2.6.2. PremixZ
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Magnesium acetate (MgAc) usually in the range of 7–15 mM 
from a 0.2 M stock solution, potassium glutamate (KGlu) usually 
in the range of 180–220 mM from a 2 M stock solution, and 
PEG-8000 usually in the range of 5–15% (w/v) from a 40% stock 
solution. Adjust the premixA with the optimal composition of 
MgAc, KGlu, and PEG to obtain the premixZ. Aliquot the pre-
mixZ and flash-freeze in liquid nitrogen. Long-time storage 
should be at −80°C, but the premixZ is stable for several months 
at −20°C and can be frozen several times. If not noted otherwise, 
reagents were purchased from Sigma-Aldrich.
Used to test the activity of the S30 extract and optimization of 
the premixZ.
 1. Prepare b-lactamase mRNA from the pRDV template DNA 
encoding the double Cys → Ala mutant of b-lactamase (23) 
using PCR with the T7B and tolAk primers (Fig. 1) (see 
Subheading 3.2), followed by in vitro transcription and puri-
fication of mRNA (Protocol 3.2 and 3.3).
 2. Set up in vitro translation reactions containing 2 mg RNA, 
0.5 ml 200 mM methionine, 10 ml S30 extract, 8.2 ml pre-
mixZ and add to 22 ml H2O. For optimization of the activity 
of the S30 extract use premixA and adjust the concentration 
of magnesium acetate, potassium acetate, and PEG-8000.
 3. Incubate at 37°C for 10 min.
 4. Add 88 ml STOP mix
 5. Use 5 ml of stopped in vitro translation for the activity assay 
with the chromogenic substrate nitrocefin (Glaxo Research 
No. 87/312, obtained from Oxoid No. SR0112) (24).
 6. Dilute nitrocefin 1:20 in b-lactamase buffer (100 mM sodium 
phosphate buffer, pH 7.0) from a stock solution (1 mg nitro-
cefin dissolved in 500 ml DMSO and stored at −20°C). For one 
reaction use 20 ml diluted nitrocefin together with 5 ml transla-
tion plus 175 ml b-lactamase buffer in a 200 ml reaction.
 7. Measure OD486 nm immediately. Follow the kinetics for approx-
imately 12 min, measuring at least once every minute.
 1. E. coli strain XL-1 blue (Stratagene, No. 200268).
 2. Expression plasmid pDST67 (20, 25), a derivative of pQE30 
(QIAGEN).
 3. 2×TY media: 5 g NaCl, 16 g tryptone, 10 g yeast extract per 
liter. Adjust pH to 7.2 with NaOH.
 4. 96-well deep well plates (ABgene, No. AB-0661).
 5. Tris-buffered saline (TBS): 50 mM Tris, 150 mM NaCl; 
adjust pH to 7.4 with HCl.
 6. TBST: TBS containing 0.05% Tween-20.
2.6.3. b-Lactamase Assay
2.7. Reagents  
for DARPin Expression 
and Binding Analysis 
of Single Clones (25)
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 7. 10% BSA in H2O.
 8. Mouse-anti-RGS(His)4 antibody (QIAGEN, No. 34650).
 9. Goat-anti-mouse IgG coupled to alkaline phosphatase 
(Sigma-Aldrich, No. A3562).
 10. pNPP substrate (p-nitrophenyl phosphate disodium salt; 
Fluka, No. 71768): stock 1 M in pNPP buffer (50 mM 
NaHCO3, 50 mM MgCl2); aliquot and store at −20°C.
 11. B-PER II detergent solution (Pierce, No. 78260).
The ribosome display vector pRDV is used to ligate the library of 
interest using gene-specific primers and insertion via the restric-
tion endonuclease sites BamHI and HindIII as indicated in Fig. 1 
(16, 26). The general elements that need to be present in a ribo-
some display vector are the T7 RNA polymerase promoter 
sequence to initiate efficient transcription and a RBS for docking 
of the ribosome to initiate translation. The PCR fragment 
(between the primers T7B and tolAk, Fig. 1) that serves as the 
template for transcription ends without a stop codon in the ORF. 
At both the 5¢ and 3¢ ends of the mRNA, stabilizing stem loops 
are incorporated to protect the mRNA from exonuclease degra-
dation (2, 27). The absence of a stop codon in the resulting 
mRNA prevents termination of translation. The fact that the 
library is fused in frame to a spacer (or tether) sequence (e.g., 
derived from the E. coli tolA gene) allows the nascent protein 
chain to exit the ribosome and fold outside of the ribosome. The 
original pRDV contains an N-terminal FLAG tag instead of an 
N-terminal Met-Arg-Gly-Ser-(His)6 tag as shown here for the 
case of the DARPin libraries (16). Both tag variants lead to good 
initiation of in vitro translation and yield ternary complexes in 
good yields.
 1. To obtain a length-defined fragment of DNA as template for 
in vitro transcription, use the outer primers T7B and tolAk in 
the following PCR reaction to introduce the T7 RNA poly-
merase promoter sequence, RBS, the stabilizing 5¢ and 3¢ 
stem loops and the tolA spacer sequence:
  5.0 ml 10× Thermopol buffer
  2.0 ml dNTPs (final concentration 200 mM each)
  2.0 ml DMSO (final concentration 5%)
  0.5 ml T7B primer (final concentration 1 mM)
  0.5 ml tolAk primer (final concentration 1 mM)
3. Methods
3.1. Insertion  
of the Library
3.2. Transcription  
of PCR Products
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  5.0 ml  library DNA [either of the initial library or of the 
amplified DNA after selection which has been 
ligated to pRDV (see Note 6)]
0.5 ml Vent DNA polymerase (2 U/ml)
Add to 50 ml H2O.
 2. Perform a hot start to increase specificity and use the following 
cycling parameters (see Note 7): 3 min at 95°C, 25 cycles: 30 s at 
95°C, 30 s at 55°C, 45 s at 72°C, final extension 5 min at 95 °C.
 3. Verify the product on an agarose gel.
 4. For in vitro transcription set up the following reaction on ice:
  20 ml 5× T7 polymerase buffer
  14 ml NTPs (final concentration 7 mM each)
   4 ml T7 RNA polymerase (20 U/ml)
   2 ml RNasin (40 U/ml)
  22.5 ml PCR product without further purification
  Add to 100 ml with H2O.
 5. Incubate the transcription for 2–3 h at 37°C (see Note 8).
 1. In order to remove all impurities from the reaction, the RNA 
needs to be purified. This can be performed in two ways:
Conventional protocol
 (a)  A LiCl precipitation can be performed to purify the 
RNA product. For this purpose, add 100 ml ice-cold 
H2O and 200 ml ice-cold 6 M LiCl to the 100 ml 
translation reaction and vortex.
 (b)  Incubate on ice for 30 min, then centrifuge at 
20,000 × g at 4°C for 30 min.
 (c)  Discard the supernatant and wash the pellet with 
500 ml ice-cold 70% EtOH ensuring that the pellet is 
not disturbed.
 (d)  Remove supernatant and dry pellet in a Speedvac 
apparatus.
 (e)  Completely dissolve the pellet in 200 ml ice-cold 
H2O and centrifuge at 20,000 × g at 4°C for 5 min to 
remove remaining precipitates.
 (f)  Transfer 180 ml supernatant to a new tube without 
disturbing the pellet. Add 20 ml 3 M NaOAc and 
500 ml ice-cold 100% EtOH, vortex.
 (g)  Incubate at −20°C for at least 30 min. Vortex and 
centrifuge at 20,000 × g at 4°C for 30 min and discard 
the supernatant.
 (h)  Wash the pellet with 500 ml ice-cold 70% EtOH, dry 
the pellet in a Speedvac apparatus, and resuspend the 
pellet in 30 ml H2O.
3.3. Cleanup  
of Template mRNA for 
In Vitro Translation
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Alternative protocol
 (a)  For purification of the RNA, small gel filtration columns 
(e.g., illustra MicroSpin™ G-50 Columns) can be used.
 (b)  Vortex the column to resuspend the material and 
break off bottom of the column.
 (c)  Place the column into a 1.5-ml tube and spin down 
at 735 × g for 1 min to pack the column material.
 (d)  Place the column into a collection tube, apply 50 ml 
sample from the transcription reaction, and centri-
fuge at 735 × g for 1 min.
 (e) Optional: DNAse I treatment before loading the col-
umn (see Note 9): Take 43 ml of the transcription 
reaction and add 2 ml of DNAse I solution (10 U/ml) 
plus 5 ml 10× dilution buffer supplied with the 
enzyme. Incubate for 10–15 min at room tempera-
ture, and then apply the sample to the column.
 2. Aliquot RNA and immediately freeze in liquid nitrogen. Store 
at −80°C.
 3. Determine the RNA concentration of a 1:100 dilution by 
OD260 nm. If the transcription worked well, a yield of 3–8 mg/ml 
for RNA after LiCl/EtOH precipitation (total yield from a 
100 ml reaction: 90–240 mg) or 1–3 mg/ml from the illustra 
MicroSpin™ G-50 Columns (total yield from a 50 ml reac-
tion: 50–150 mg) should be obtained.
 1. For one in vitro translation reaction, set up the following mix 
on ice:
  2.0 ml 200 mM methionine
  41 ml premixZ with optimized composition
   x ml  in vitro transcribed RNA (total 10 mg, volume 
 follows from RNA concentration; see Note 10)
  50 ml  S30 extract and add to 110 ml with H2O (for prepa-
ration of the S30 extract, see Subheading 3.12)
  Add 0.625 ml PDI if your library scaffold requires the 
formation of disulfide bonds.
 2. Mix carefully by pipetting up and down and incubate the 
reaction at 37°C for 10 min, the time found optimal for 
DARPins. The incubation time and temperature must be 
optimized for each library based on different constructs.
 3. Stop the reaction by addition of 440 ml ice-cold STOP mix.
 4. Mix by pipetting up and down and centrifuge at 20,000 × g at 
4°C for 5 min. Transfer 500 ml supernatant to a fresh tube and 
use 100 ml per well when performing selection in plates or 250 ml 
per tube when performing selections in solution for either the 
target-containing or control reaction (see Subheading 3.5).
3.4.  In Vitro Translation
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Express and purify the target by methods of your choice. To 
immobilize the target for capturing the ternary complexes it is 
recommended to biotinylate the target. This is the method of 
immobilization found to be most robust by far to stringent 
washing, including washing with detergents. The advantage of 
immobilizing biotinylated targets is that it is very general, and it 
works equally well for proteins, peptides, oligonucleotides, and 
small molecules. Furthermore, by avoiding any direct binding 
to plastic surfaces, the structure of the target is maintained. 
Finally, the nonbiotinylated version of the target is a convenient 
competitor in off-rate selections and in the specificity screening 
of single clones. Biotinylation can be achieved in two ways (see 
Note 12):
 1. Fuse the target to an AviTag and biotinylate it in vivo or 
in vitro using the E. coli biotinylation enzyme BirA (21) fol-
lowing the guidelines posted on the Avidity webpage (http://
www.avidity.com).
 2. Alternatively, biotinylate surface lysine amino acid residues 
using NHS-biotin reagents from Pierce following the manu-
facturer’s instructions.
 1. Coat wells of a 96-well Maxisorp plate with 100 ml of a 66 nM 
neutravidin or streptavidin solution in TBS and close with an 
adhesive plate sealer (see Notes 13 and 14). Store overnight 
at 4°C or for 1 h at room temperature. Invert the plate and 
shake out the solution, dry on paper towels, and wash the 
wells three times with 300 ml TBS.
 2. Block the wells with 300 ml 0.5% BSA in TBST per well, seal 
and incubate on an orbital shaker for 1 h at room tempera-
ture. Shake out blocking solution and dry on paper towels.
 3. Immobilize 100 ml biotinylated target at a concentration of 
100–200 nM (can be decreased in later rounds) in 
TBST/0.5% BSA and TBST/0.5% BSA only for control 
wells. Seal and incubate on an orbital shaker at 4°C for 1 h. 
Wash the plate three times with 300 ml ice-cold TBST and 
once with 300 ml ice-cold WBT. Remove WBT only when 
the stopped translation reaction can be added to the wells 
(see Subheading 3.4).
 4. Add the stopped in vitro translation, seal the plate, and 
incubate the binding reaction at 4°C for 1 h. Wash the wells 
with 300 ml ice-cold WBT containing 0.1% BSA for eight to 
ten times. Use two fast washes removing the buffer immedi-
ately, followed by incubations starting at 5 min and extending 
to 15 min in later rounds. In these longer incubations 
binders with fast off-rates will dissociate and subsequently 
be washed away.
3.5. Selection  
(See Note 11)
3.5.1. Target Protein 
Preparation
3.5.2.  Selection in Plates
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 5. For elution of the RNA, add 100 ml EB containing EDTA to 
release the mRNA from the captured protein–mRNA–ribosome 
complexes and freshly added S. cerevisiae RNA (final concentration 
50 mg/ml) to block the surface of the tubes and perhaps to act as 
competing substrate for any residual RNases. Incubate at 4°C 
for 10 min and add to 400 ml lysis buffer of the High Pure 
RNA purification kit on ice. Repeat the elution step and col-
lect the second elution in the same tube. After vortexing the 
RNA is stable and can be processed at room temperature until 
elution from the column (see Subheading 3.6).
 1. Starting from the stopped and centrifuged in vitro translation 
reaction (see Subheading 3.4), divide the reaction into two 
aliquots of 250 ml and add 250 ml of STOP mix. Add 40 ml of 
streptavidin-coated magnetic beads that were washed two 
times with 500 ml TBS and blocked with 500 ml TBST/0.5% 
BSA for 1 h in a 2-ml tube as preselection step (see Note 14). 
Rotate at 4°C for 1 h.
 2. Transfer the supernatant to a blocked 2-ml tube and add to 
100–200 nM of biotinylated target (omit target in the control 
reaction) and incubate rotating at 4°C for 1 h (see Note 15).
 3. Transfer the supernatant to a blocked tube containing 40 ml 
of streptavidin-coated magnetic beads and capture the ter-
nary complexes rotating at 4°C for 30 min. Wash with 500 ml 
ice-cold WBT containing 0.1% BSA as indicated above (see 
Subheading 3.5.2). Separate captured complexes using a 
magnetic separator between each washing step.
 4. Proceed with the elution and purification of RNA as described 
for the selection on plates (see Subheading 3.5.2).
To increase the affinities of the library members, it is best to select 
for those having the lowest dissociation rate constant (off-rate) 
from the target (7, 13, 15, 28, 29). This off-rate selection can be 
applied for the improvement of known binders (after mutagen-
izing the gene for defined binders and thus creating a new library), 
but also during the initial selection from the original library. In 
this off-rate selection step an excess of nonbiotinylated target is 
added after the binding reaction has already been equilibrated for 
1 h. Any fast dissociating binder will be immediately occupied by 
nonbiotinylated target and thereby prevented from being cap-
tured with biotinylated target on streptavidin or neutravidin. 
Conversely, any high-affinity binder with a slow off-rate will retain 
its biotinylated target and thus can be captured. The optimal 
duration of competitor incubation and the excess concentrations 
depend on the expected off-rates. As a general guideline, for the 
first off-rate selection a 2-h incubation with a 10 to 100-fold 
excess of competitor is recommended, and a 14-h incubation 
3.5.3. Selection in Solution
3.5.4. Affinity Maturation 
by Competition with 
Non-labeled Target 
(Off-Rate Selection)
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with a 1,000 to 10,000-fold excess of competitor in later rounds 
may be appropriate. Then proceed with washing and elution of 
the bound ternary complexes as above.
 1. Apply the lysis buffer/eluate mixture on the column of the 
High Pure RNA isolation kit (see Note 16; Optional: as a 
positive control also purify 2 ml of the input RNA from the 
in vitro transcription diluted in 200 ml EB) and centrifuge at 
8,000 × g for 1 min. Discard the flow-through.
 2. Add 100 ml diluted DNAse I solution (1.8 U/ml) directly 
onto the column filter and incubate at room temperature for 
15 min (see Note 17). Add 500 ml wash buffer 1 and centri-
fuge at 8000 × g for 1 min. Discard flow-through.
 3. Wash with 500 ml wash buffer 2, centrifuge and discard flow-
through.
 4. Add 100 ml wash buffer 2 and centrifuge at 13,000 × g for 
2 min to remove any residual EtOH.
 5. Elute with 50 ml elution buffer and incubate for 2 min before 
centrifugation at 8,000 × g for 1 min into a fresh 1.5-ml 
RNAse-free tube.
 6. Freeze the remaining sample of eluted RNA in liquid nitro-
gen and store at −80°C (see Notes 10 and 18).
 1. Transfer two times 12.5 ml of eluted RNA to fresh 1.5-ml 
tubes (see Note 19).
 2. Denature the eluted RNA at 70°C for 10 min and chill on ice.
 3. Set up the following reverse transcription (RT)-mix (total of 
7.75 ml) per RT reaction on ice:
  0.25 ml WTC4 primer (final concentration 1.25 mM)
  0.5 ml  dNTPs (final concentration 125 mM of each 
nucleotide)
  0.5 ml RNasin (40 U/ml)
  0.5 ml  AffinityScript™ Multiple Temperature Reverse 
Transcriptase (50 U/ml)
  2.0 ml 10× AffinityScript buffer
  2.0 ml DTT (final concentration 10 mM)
  2.0 ml H2O
 4. Distribute 7.75 ml RT-mix per RT reaction to the 12.25 ml 
samples of denatured RNA.
 5. Incubate at 50°C for 1 h.
 6. Use 2–5 ml as template for PCR using the inner primers 
WTC4 and EWT5s.
 7. Freeze the rest of the cDNA in liquid nitrogen and store at 
−20°C.
3.6. Recovery  
of Eluted RNA
3.7. Reverse 
Transcription  
of DARPin mRNA
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The standard protocol for Vent DNA polymerase (NEB) is shown 
below. If another DNA polymerase or primers are used, the reac-
tion conditions might have to be adapted.
 1. Set up the following reaction mix per sample:
  2–5 ml cDNA
  5.0 ml 10× Thermopol buffer (NEB)
  2.0 ml  dNTPs (final concentration 200 mM of each 
nucleotide)
  2.5 ml DMSO (final concentration 5%)
  0.5 ml WTC4 primer (final concentration 1 mM)
  0.5 ml EWT5s primer (final concentration 1 mM)
  0.5 ml Vent DNA Polymerase (2 U/ml)
  Add to 50 ml with H2O
 2. Perform a hot start PCR to reduce unspecific amplification. 
Use the following cycling parameters: 3 min at 95°C, 25 
cycles: 30 s at 95°C, 30 s at 55°C, 45 s at 72°C, and final 
extension 5 min at 95°C (see Note 20).
 3. Verify the product on an agarose gel (see Note 21).
 1. Purify PCR products either by excision of the according bands 
from the agarose gel and subsequent purification or direct purifi-
cation over commercially available columns, for example, of the 
NucleoSpin extract II kit. Elute in a small volume of 20 ml.
 2. Digest ³ 150 ng of the PCR product with the corresponding 
restriction enzymes, e. g., NcoI and HindIII for DARPin selec-
tions, in a final volume of 30 ml at 37°C for 2 h (see Note 22).
 3. Purify digested PCR product using the NucleoSpin® Extract 
II DNA purification kit. Elute in 15 ml elution buffer supplied 
with the kit.
 4. Ligate the PCR fragments into the ligation-ready pRDV plas-
mid using 100 ng of digested pRDV and the digested PCR 
product with a molar ratio of vector to insert of 1:5–7 in a 
final volume of 10 ml. Add 1 U of T4 DNA ligase and 1 ml 
ligase buffer. Incubate 30–60 min at room temperature. Use 
this ligation as PCR template with the T7B and tolAk primers 
(see Subheading 3.2) or perform an error-prone PCR to 
increase diversity (see Subheading 3.10).
 1. Set up reactions introducing different mutational rates using 
various concentrations in the range of 1–20 mM of the nucle-
otide analogs dPTP and 8-oxo-dGTP (see Note 23): 10 ng 
pRDV_DARPin template, 250 mM dNTPs each, 1 mM T7B 
primer and tolAk primer, 1× polymerase buffer, 1.5 mM 
MgCl2 and 0.2 ml Platinum® Taq DNA Polymerase in a 50 ml 
reaction.
3.8. Amplification  
of cDNA Coding  
for DARPins
3.9. Incorporation  
of Promoter Elements, 
RBS, tolA Spacer  
and RNA-Stabilizing 
Stem Loops
3.10.  Error-Prone PCR
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 2. Apply the following cycling parameters (must be adapted 
according to primers and template): 3 min at 95°C, 25 cycles: 
30 s at 95°C, 30 s at 50°C, 1 min at 72°C, and final extension 
5 min at 95°C.
 3. Verify the product on an agarose gel.
 4. Mix PCR products in equimolar amounts to serve as template 
for the in vitro transcription (see Subheading 3.2, step 4).
 1. After RT-PCR (see Subheadings 3.7 and 3.8) prepare the 
DARPin pool after enrichment has been observed for subclon-
ing into a prokaryotic expression plasmid using the endonu-
cleases BamHI and HindIII. Enrichment is indicated by a much 
stronger PCR band recovered from a well with immobilized 
target than from a control well without immobilized target.
 2. Ligate the PCR fragment into pDST67 (20, 25) as fusion 
with the sequence coding for a N-terminal MRGS(H)6 tag 
for purification.
 3. After transformation into E. coli XL1-Blue pick single clones 
and inoculate in deep 96-well plates in 1 ml 2×TY/1% 
glucose/amp (100 mg/ml) grow overnight at 37°C while 
shaking at 540 rpm on an orbital shaker.
 4. Transfer 100 ml of each culture to 900 ml fresh media and 
grow at 540 rpm for 1 h at 37°C.
 5. Induce with 0.5 mM IPTG (add 100 ml media containing 
5.5 mM IPTG) and grow an additional 3–5 h at 37°C.
 6. Harvest cells by centrifugation at 400 × g for 10 min, and 
 discard supernatant.
 7. Resuspend pellet in 50 ml B-PER II detergent and lyse cells 
for 15–30 min on an orbital shaker at 500 rpm.
 8. Add 1 ml TBST/0.1% BSA and centrifuge to remove debris.
 9. Use 10 ml (using a predilution of 1:100 in TBST/0.1% BSA 
can give you a better indication of the affinity of the binders 
when they are in the mM to low nM range) for ELISA. Binders 
with even higher affinity will still fully saturate the  immobilized 
target and can only be distinguished in ELISA by inhibition 
with low concentrations of soluble target.
 10. For ELISA, coat wells with 100 ml of 66 nM neutravidin in TBS 
for 1 h at room temperature or overnight at 4°C. Wash two times 
with 300 ml TBS. Dry plate on paper towels after each step.
 11. Block with 300 ml TBST/0.5% BSA for 1 h at room 
temperature.
 12. Invert plate and shake out liquid and immediately add 100 ml 
of the biotinylated target (10–100 nM) in TBST/0.1% BSA. 
Incubate 1 h at 4°C or room temperature on an orbital shaker 
(see Note 24). Wash three times with 300 ml TBST.
3.11. Initial Analysis  
of Selected Individual 
Library Members in a 
96-Well Format (22)
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 13. Add 100 ml DARPin extract from step 9. Incubate 1 h at 4°C 
or room temperature on an orbital shaker. Wash three times 
with 300 ml TBST.
 14. Add 100 ml mouse-anti-RGS(His)4 antibody in a 1:500 dilu-
tion. Incubate 1 h at 4°C or room temperature on an orbital 
shaker. Wash three times with 300 ml TBST.
 15. Add 100 ml goat-anti-mouse antibody coupled to alkaline 
phosphatase in a 1:20,000 dilution. Incubate 1 h at 4°C or 
room temperature on an orbital shaker. Wash three times 
with 300 ml TBST.
 16. Add 100 mlpNPP substrate solution. Incubate until color 
development at 4° to 37°C depending on the stability of the 
target and the library scaffold and determine OD405 nm.
 1. Grow a 100-ml culture of E. coli MRE600 in incomplete rich 
medium overnight at 37°C.
 2. Transfer 10 ml of the overnight culture in 1 l of fresh media 
in a 5-l baffled shaker flask and grow until OD600 nm of 1.0–1.2 
at 37°C while shaking at 230 rpm. This procedure can be 
scaled up to your needs, and 1 l culture usually yields 10–15 ml 
of S30 extract. The S30 extract is stable for years when stored 
at −80°C.
 3. Chill cultures for 10 min on an ice water bath with gentle 
shaking.
 4. Centrifuge cells at 3,500 × g at 4°C for 15 min and discard 
supernatant.
 5. Wash the pellet three times with 50 ml of ice-cold S30 buffer 
per 1 l culture. It is best to resuspend cells with plating beads 
or on a magnetic stirrer using a sterile stir bar.
 6. Freeze the cell pellet in liquid nitrogen and store for a maxi-
mum of 2 days at −80°C or continue immediately.
 7. Resuspend the cell pellet (use 50 ml ice-cold S30 buffer per 
1 l of culture), centrifuge at 4,000 × g. Discard supernatant 
and resuspend pellet in 4 ml S30 buffer per g wet cells (typi-
cally 1 l of culture yields 1.5–2.0 g cell pellet).
 8. Lyse the cells by one single passage through a French press 
applying 1,000 psi or an EmulsiFlex at ~17,000 psi.
 9. Centrifuge cells at 20,000 × g (SS-34) at 4°C for 30 min. 
Transfer supernatant to clean centrifuge bottle(s) and repeat 
this step.
 10. Add 1 ml of preincubation mix to each 6.5 ml of cleared 
supernatant (usually 1 l culture will yield 8–10 ml of S30 
extract) and slowly shake at 25°C for 1 h. In this time all 
3.12. Preparation  
of S30 Extract (30–32)
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endogenous mRNA will be translated and cellular nucleases 
will degrade mRNA and DNA (33).
 11. Dialyze the S30 extract in a tubing with a MW cutoff of 
6,000-8,000 Da (Spectrum Laboratories SpectraPor No. 
132650) against a 50-fold volume of S30 buffer at 4°C three 
times for 4 h.
 12. Centrifuge S30 extract at 4,000 × g at 4°C for 10 min. If the 
library members and target are devoid of disulfide bonds, 
1 mM DTT can be added to the extract. Aliquot at 4°C in 
suitable volumes (e.g., 55 ml is sufficient for one in vitro trans-
lation reaction, 110 ml for two) since it should not be refrozen 
to guarantee best activity. Flash freeze in liquid nitrogen and 
store at −80°C.
 1. Use RNAse-free water, chemicals, and consumables. Most 
commercially available water is RNase-free or can be gener-
ated using a membrane microfiltration system, e.g., MilliQ 
from QIAGEN, to produce ultrapure water. Alternatively, you 
can use 0.1% DEPC (diethylpyrocarbonate), which reacts with 
histidine residues but also other nucleophilic groups and 
therefore inactivates RNases, but for the same reason it cannot 
be used, for example, with Tris-buffers. Chemicals should be 
kept separate from the common chemical shelf and handled 
only with gloves and a flamed spatula to avoid RNase con-
tamination. Purchase only RNase-free plastic consumables. If 
necessary you can bake glass bottles and pipettes at 180°C for 
6 h.
 2. The buffer composition may be adjusted to the requirements 
of the library and target, but it is important that the wash 
buffer contains 50 mM Mg2+ to stabilize the ribosome. It is 
recommended to test buffer conditions with a known binder 
to ensure stability of the nascent chain complex.
 3. Different reverse transcriptases [AffinityScript™ Multiple 
Temperature Reverse Transcriptase, SuperScript™ II (Invitrogen, 
No. 18064-022), ThermoScript™ (Invitrogen, No. 12236-
014), and QuantiTect (QIAGEN, No. 205310)] were tested 
for efficiency on DARPin sequences. With exception of 
QuantiTect the yield obtained was comparably high with all 
other reverse transcriptases.
 4. Previously Phusion™ High-Fidelity DNA Polymerase (New 
England Biolabs, No. F-530S) has also been used (26, 30). 
Different DNA polymerases were tested [VentR
® DNA 
Polymerase, Herculase® II Fusion DNA Polymerase (Stratagene, 
4. Notes
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No. 600677), Expand High Fidelity PCR System (Roche 
Diagnostics, No. 11732641001]. The DNA polymerase mix 
from the Expand High Fidelity PCR System gave the lowest 
yield of PCR product, while Herculase II gave the highest 
amount of side products. Therefore, we now routinely use 
VentR
® DNA Polymerase for amplification of DARPin 
sequences. Since the yield was highest with the Herculase II it 
might be a good alternative to increase the yield of PCR prod-
uct or for amplification of other library scaffolds.
 5. Use the home-made RNA polymerase buffer (see 
Subheading 2.4) as indicated for maximum yield of RNA. 
Commercial buffers have not worked very well at this step when 
the PCR product is directly used without further purification.
 6. In round one ensure that the number of molecules actually 
exceeds the library size. Conversely, in a newly constructed 
library, the diversity cannot be higher than the number of 
molecules used in this step. In later rounds, an enrichment is 
obtained, and it is generally sufficient to use ~50 ng of pRDV_
DARPin template.
 7. The PCR products can be used without additional purification.
 8. Optionally, the transcribed RNA can be analyzed on a dena-
turing formaldehyde agarose gel following standard proce-
dures (34). The mRNA product should give a sharp band. 
A smear or no product indicates RNase contamination, which 
needs to be eliminated and the step repeated. If the band is 
sharp but the yield is lower than expected: Obtain more start-
ing DNA template by not purifying the PCR product that is 
used as template, as the quality is usually sufficient even with-
out purification, and do use the home-made RNA polymerase 
buffer (Subheading 2.4) for better transcription yield. If the 
products are not of the expected size, optimize the PCR con-
ditions depending on your template and primers.
 9. In some cases the template DNA might bind unspecifically to 
the target, for example, if the target is highly positively 
charged, and then it is recommended to remove this contami-
nation by DNAse I treatment before the actual selection. 
Always freeze small aliquots of DNAse I and store at −20°C. 
Do not refreeze or vortex solutions containing DNAse I, 
because the enzyme is very sensitive to denaturation.
 10. Always freeze RNA immediately after use and only thaw when 
needed to avoid degradation.
 11. For the selection, some general considerations need to be 
pointed out. Always use the same target preparation through 
all of the selection and screening rounds, and ensure its qual-
ity and account for its stability over the duration of the exper-
iment. If the target denatures, epitopes present in the native 
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protein will vanish, and such binders will be lost. Account for 
high diversity especially in the first round by using sufficient 
starting library. Start selections with a higher number of DNA 
template molecules than the diversity of the library. To extract 
all putative binders in the library use a larger surface area to 
immobilize the target in the first round. The first round 
should, in general, not be highly selective; it is more impor-
tant to capture the full diversity of binders, as a binder lost at 
this stage can never be recovered. In general, it is recom-
mended to perform the selection in duplicates to monitor the 
selection quality. It is recommended to switch between neu-
travidin (a chemically modified derivative of avidin) and 
streptavidin, or even switch between selections on immobi-
lized target and target in solution during the selection pro-
cess, to focus selection on binding to the target, rather than 
on streptavidin/neutravidin or any other surface features. 
If high-affinity binders in the pM range are needed, include 
the introduction of additional random mutations using error-
prone PCR and increase stringency by applying off-rate selec-
tions. Perform one cycle of nonstringent selection including 
an error-prone PCR followed by a round of off-rate selection 
without error-prone PCR (see Subheading 3.5.4). The ratio-
nale is that error-prone PCR will generate many nonfunc-
tional molecules. First, all functional molecules should be 
recovered by a nonstringent selection, then from this pool of 
functional (randomized) molecules, the best ones should be 
recovered. Use these to perform a stringent round using off-
rate selection. Start at 10–100-fold excess competitor; increase 
to 100–10,000-fold in later rounds, if feasible (35). These 
two rounds should be followed again by a nonstringent round 
without any additional selection pressure; simply to amplify 
the rare molecules. Perform this cycle of error-prone PCR, 
off-rate selection, and nonstringent round two to three times 
before analyzing single clones (see Subheading 3.10).
 12. Using the AviTag has the advantage that all biotinylated pro-
teins are labeled uniformly and remote from epitopes, which 
might interfere with later use and are labeled only once, lead-
ing to a more homogenous target preparation. Avoid the 
presence of a Met-Arg-Gly-Ser-(His)6 tag (“RGS-His-tag”) 
on the biotinylated target, rather use a (His)6 tag for purifica-
tion, since the detection of DARPins bound to the target is 
performed using an anti-RGS(His)4 antibody (see 
Subheading 3.10). Make sure your target sample is devoid of 
free biotin. Biotin removal requires an extensive dialysis, for 
example, four times against an 100-fold volume buffer for 4 h 
each. Nonbiotinylated target can be removed using a mono-
meric avidin column following the manufacturer’s instruc-
tions (Pierce, No. 53146).
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 13. Use one well as nontarget control and two wells with immo-
bilized target in later rounds as mutual controls for enrich-
ment. When starting from the libraries in round 1 it is 
recommended to use a larger surface, for example, four wells 
with immobilized target.
 14. To remove unspecifically binding ribosomal complexes it is 
recommended to use a preselection on BSA-blocked wells 
coated only with neutravidin or streptavidin, but omitting the 
target protein, except for round 1, where this “prepanning” 
should not be done. For prepanning, the preparation of addi-
tional wells and incubation of the ternary complexes from the 
in vitro transcription for 30–60 min are necessary before trans-
ferring the solution to the target-coated or control wells.
 15. The amount of target can be reduced to 100 pM, for exam-
ple, when performing an off-rate selection, and thus a high 
amount of competitor can be added. At even lower target 
concentrations the unspecific binding might dominate over 
target binding, however, and thus specificity of binding must 
be carefully controlled.
 16. RNA isolation can also be performed with the RNeasy mini 
kit (QIAGEN, No. 74104) with comparable yield of result-
ing PCR product.
 17. This step is highly recommended to avoid amplification of 
nonselected template DNA that has been carried over through 
all steps of the selection procedure. See also Note 9 for han-
dling of DNAse I.
 18. The RNA should be stable for years at −80°C, but we recom-
mend to immediately proceed with cDNA synthesis and PCR 
amplification for best recovery of sequences of putative binders.
 19. Use one sample without addition of reverse transcriptase as 
control. The result of the following PCR will be a measure for 
the quality of the selection regarding DNA carry-over from the 
input DNA and putative overcycling (see Notes 17 and 20).
 20. Depending on the round of selection more or fewer cycles 
could be advantageous. In the first round, 32–40 cycles are 
recommended to obtain sufficient product. After more rounds 
of selection specific binders are being enriched, therefore, the 
output of eluted RNA molecules increases. By lowering the 
cycle numbers in round 2 to between 28 and 35 and in all fol-
lowing rounds to 25, unspecific amplification can be reduced 
to a minimum. In addition, note that when the selection pres-
sure increases, for example, after off-rate selection, the yield of 
PCR product might decrease. In this case use more cycles.
 21. If the quality and amount (<10 ng/ml) of the PCR product 
was not satisfactory repeat the PCR. Never reamplify the PCR 
product, because this might lead to unspecific amplification 
of unwanted by-products.
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 22. In parallel, digest the ribosome display vector (pRDV) with 
the same restriction enzymes, for example, NcoI and HindIII 
for DARPin selections. Purify the plasmid backbone using 
extraction from a preparative agarose gel. It is recommended 
to use a larger preparation to last for several selection rounds 
and/or multiple target selections: Test the quality of the 
digested plasmid by ligation and transformation and/or PCR 
on the ligation mix to evaluate the level of religation and 
therefore quality of the ligation-ready plasmid.
 23. Add different concentrations of the nucleotide analogs, for 
example, 0, 3, and 10 mM. Up to 20 mM can be used, but the 
amount of product is greatly reduced at this concentration. 
The mutational load per kb under the conditions described is 
1.5 mutations with 1 mM nucleotide analogs and 3.2 muta-
tions with 3 mM nucleotide analogs using Platinum Taq 
 polymerase. These numbers refer to fresh nucleotides and 
can vary if the nucleotides are no longer incorporated well, 
for example, by hydrolysis of the triphosphate. The use of a 
low to medium mutational load per selection, but repeating 
over several rounds, might be beneficial over a high muta-
tional load which might result in a high number of misfolded 
library members in the pool.
 24. The incubation temperature depends on the stability of the 
target and library scaffold.
 25. Some applications, e.g., for therapy, require high stability of 
the therapeutic agent (36). Selection for high stability can 
also be achieved with ribosome display. This is best achieved 
by first making the whole population unable to fold, by 
introducing a reversible destabilization, and then selecting 
for compensating mutations, and finally removing the desta-
bilization again. For example, most antibody domains 
require disulfides for stability, which form only under oxi-
dizing conditions. A destabilization and increase in aggrega-
tion of the antibody fold is usually observed when the 
disulfides are removed (6, 37). Using a reducing environ-
ment during the selection, scFv antibody fragments could 
be evolved that were able to fold under reducing conditions 
correlating with conditions in the cytosol, and they showed 
higher stability than the starting molecule in the absence of 
the disulfide bonds (7), but also after the disulfide bonds 
were allowed to form again. Antibody fragments with these 
improved biophysical property can be used in biomedical 
applications with disulfides formed, but they also make an 
intracellular application (as “intrabodies”) (38) more feasi-
ble. In addition, rational design of the antibody framework 
(39) could contribute to the development of stability-
improved, antibody-based therapeutics.
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